Aurora kinase (AURK)A improves the stability of MYCN by inhibiting its protease-dependent degradation and is an alternative target in MYCN-directed therapies (44); miR-186 in NKEVs was shown to reduce MYCN and AURKA expression, thereby inhibiting proliferation and inducing apoptosis in NB cells. The gene discussed is MYCN; the disease is neuroblastoma.